COVID-19 pneumonia. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients in Umifenovir received Umifenovir 200 mg TDS for 7 days. Intervention 2: Control group: Patients received Lopinavir-Ritonavir 50-200 mg in 2 Tab BID for 7
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Laboratory confirmed COVID-19 with RT-PCR Oxygen saturation < 93% Fever more than 72 hours before admission Bilateral pulmonary infiltration Age over 18 years old
Exclusion criteria
Exclusion criteria: Chronic kidney disease (Stage IV and V) Acute kidney injury Pregnancy or breastfeeding Drug allergy history Chronic liver disease (Child pugh C) Mild phase of COVID-19 Critical phase of COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse drug reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Death. Timepoint: At the end of the study. Method of measurement: Medical record.;Need of mechanical ventilation. Timepoint: Daily. Method of measurement: Medical record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPayam Tabarsi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed